THAR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Tharimmune Inc (THAR.O) is -0.48, compared to its 5-year average forward P/E of -0.74. For a more detailed relative valuation and DCF analysis to assess Tharimmune Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.74

Current PE

-0.48

Overvalued PE

0.18

Undervalued PE

-1.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 5974.89% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 5974.89% over the last month.

Sold

Bought

THAR News & Events

Events Timeline

No data

News

8.5

2025-12-22Benzinga

Clearwater Analytics (CWAN) Acquired by Private Equity Consortium for $8.4 Billion

3.5

2025-12-18PRnewswire

Tharimmune Leverages Canton Coin to Accelerate Blockchain Adoption

5.0

2025-12-12Businesswire

Tharimmune Appoints Jacob Asbury as CFO to Drive Digital Asset Strategy

People Also Watch

Frequently Asked Questions

What is Tharimmune Inc (THAR) stock price today?

The current price of THAR is 2.79 USD — it has decreased -4.12 % in the last trading day.

What is Tharimmune Inc (THAR)'s business?

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

What is the price predicton of THAR Stock?

Wall Street analysts forecast THAR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for THAR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tharimmune Inc (THAR)'s revenue for the last quarter?

Tharimmune Inc revenue for the last quarter amounts to -2.09M USD, decreased -45.84 % YoY.

What is Tharimmune Inc (THAR)'s earnings per share (EPS) for the last quarter?

Tharimmune Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Tharimmune Inc (THAR)'s fundamentals?

The market is revising No Change the revenue expectations for THAR for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -6.38%.

How many employees does Tharimmune Inc (THAR). have?

Tharimmune Inc (THAR) has 2 emplpoyees as of January 10 2026.

What is Tharimmune Inc (THAR) market cap?

Today THAR has the market capitalization of 97.78M USD.